Clinical Trial Update: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial evaluating the combination of tislelizumab and SX-682 for resectable pancreatic cancer; the study is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• SX-682
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Lei Zheng | Conditions: Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING